News Room

Plexus Ventures to Assist Ferring Pharmaceuticals with Distribution Agreement for BioLon™

April 11, 2017

Philadelphia PA -- Plexus Ventures, a global pharmaceutical consulting firm, announces its engagement with Ferring Pharmaceuticals, a privately-held biopharmaceutical company recognized around the world. Ferring has appointed Plexus Ventures to assist the company in securing a U.S. distributor for BioLon™ (1% sodium hyaluronate), a viscoelastic product used in cataract and other ophthalmic surgery. BioLon was approved by the FDA in 1998 and is manufactured by Ferring’s wholly-owned subsidiary Bio-Technology General (Israel) Ltd.

“BioLon is used by ophthalmic surgeons around the world,” said Dov Kanner, Executive Chairman, Bio-Technology General. “This proven product addresses a large U.S. market and we look forward to working with Plexus Ventures in identifying a capable U.S. distributor”.

Bob Moran, President of Plexus Ventures, added: “In recent years, Plexus Ventures has assisted Ferring Pharmaceuticals with a number of business development projects. We look forward to working with our colleagues in Ferring on this assignment.”

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit

Bio-Technology General (Israel) Ltd.

Bio-Technology General (BTG) is the leading fully integrated biopharmaceutical company in Israel. Established in 1980, the Company has a proud and pioneering tradition in the biotech arena. As a wholly-owned subsidiary of Ferring Pharmaceuticals since 2005, BTG plays a vital role in Ferring’s expanding global manufacturing and development activities.

About Plexus Ventures

Now in its 27th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.